ArticleiScience2026
L-asparaginase reversibly suppresses CD40-mediated B cell activation and antigen-presenting function by metabolic restriction.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic reprogramming and nutrient uptake are essential for immune cell activation and adaptation. While asparagine is normally a non-essential amino acid, extracellular depletion by L-asparaginase (ASNase) is widely used to treat acute lymphoblastic leukemia and lymphoma. However, its effects on non-malignant B cells remain poorly understood. Using a model of CD40-mediated human B cell activation, we investigated the impact of ASNase on primary human B cells. Even at low, clinically sub-therapeutic concentrations, ASNase induced profound metabolic alterations, reducing glycolytic and mitochondrial respiratory capacity. This was accompanied by impaired proliferation and cluster formation without increasing cell death. Instead, ASNase suppressed B cell activation and antigen-presenting cell (APC) function while promoting the emergence of regulatory B cell phenotypes and immunosuppressive cytokine expression in a subset of cells. Supplementation with asparagine or glutamine restored APC function and proliferation, with glutamine showing slightly greater efficacy. These findings suggest that ASNase reversibly suppresses pro-inflammatory B cell functions through extensive metabolic reprogramming and may warrant evaluation as a potential immunosuppressive agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.